AI-Cybernetics Collaboration Revolutionizes Pharma
Conduit teams with SARBORG to use AI for optimizing drug development and reducing human error.
Conduit Pharmaceuticals has partnered with SARBORG Limited to integrate advanced AI and cybernetics into its operations. The collaboration focuses on improving drug repurposing, discovery, clinical trial monitoring, and asset management by reducing human error, accelerating timelines, and cutting costs. Sarborg’s platform will provide predictive models and real-time dashboards to enhance decision-making and optimize drug development processes.
Conduit gains a perpetual, royalty-free right to the technology developed through the partnership, emphasizing innovation and efficiency. CEO Dr. David Tapolczay highlights this as a transformative step toward revolutionizing drug development strategies.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion